

Luxembourg, 02/08/2023

**Public**

## Environmental and Social Data Sheet<sup>1</sup>

### Overview

Project Name:	AKKERMANSIA (IEU LS)
Project Number:	2022-0917
Country:	Belgium
Project Description:	<i>The project covers R&amp;D (including clinical trials), R&amp;D management as well as the early commercialisation expenses of the Borrower, aiming at exploiting the unique properties of Akkermansia muciniphila, a bacteria that prevents and reverses leaky gut, a root cause of many health conditions.</i>
EIA required:	no
Invest EU sustainability proofing required	yes
Project included in Carbon Footprint Exercise <sup>2</sup> :	no

### Environmental and Social Assessment

#### Environmental Assessment

The promoter is a Belgian company founded based on the discovery of the benefits of Akkermansia muciniphila to humans in a number of conditions. It is an early-stage SME and commercialisation of food supplements began late 2022. The promoter's investments through this operation concern R&D; specifically clinical trials and research to optimize manufacturing processes.

The project's activities are not listed in Annex I nor Annex II of the EU EIA Directive 2011/92/EU amended by Directive 2014/52/EU. No new facilities are expected to be constructed.

The Promoter is in scope but screened out of the PATH framework as it does not operate in a high-emitting sector and is not considered as a highly-vulnerable counterpart.

#### Climate Assessment

<sup>1</sup> The information contained in the document reflects the requirement related to the environmental, social and climate information to be provided to Investment Committee as required by the Invest EU Regulation and it represents the equivalent of the information required in the template of the InvestEU sustainability proofing summary

<sup>2</sup> Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO<sub>2</sub>e/year absolute (gross) or 20,000 tonnes CO<sub>2</sub>e/year relative (net) – both increases and savings.



Luxembourg, 02/08/2023

The project has been assessed for Paris alignment and is considered to be aligned both with low-carbon and resilience goals per the policies set out in the Climate Bank Roadmap and/or associated guidance and other relevant documents (e.g. the Energy Lending Policy).

### **Social Assessment**

The company's R&D facilities and practices comply with relevant national and EU regulations and the promoter maintains adequate internal procedures and management practices. The use of animal testing is minimised and in line with the EU Directive 2010/63/EU.

The company complies with Clinical Trials Directive (EC) No. 2001/20/EC and national implementing legislation in the EU Member States, which regulated clinical trials in the EU until the Regulation's entry into application.

The company has a sound Occupational Health and Safety policy, including a commitment to comply with legal requirements.

The project does not have any significant negative social impacts.

### **Conclusions and Recommendations**

The Promoter has effective policies and operating procedures in place, which are in line with industry standards.

The project concerns investment in research and development which are not listed in Annex I nor Annex II of the EU EIA Directive 2011/92/EU amended by Directive 2014/52/EU.

Sustainability proofing conclusion: The project is carried out in compliance with applicable national and EU environmental and social legislation. Based on the environment, climate and social (ECS) information, the review of the ECS risks and impacts and the management systems in place, the project is deemed to have non-significant ECS risks and impacts. No further sustainability proofing is required.

Considering the above, including the capacity of the promoter and the overall net positive social impact of RDI, this project is deemed acceptable for the Bank's financing under environmental and social terms.